Partnership quadruples distribution of Corvalen(R) (D-ribose) products to
MINNEAPOLIS, and GREEN BAY, Wis., Oct. 29 /PRNewswire/ -- Bioenergy Life Science -- The Ribose Company, and Integrative Therapeutics, Inc. (ITI), a division of Enzymatic Therapy Inc. (ETI), today announced that they have entered into an exclusive co-marketing alliance. ITI will now sell the Corvalen(R) line of products, developed by Bioenergy Life Science, to its established health care practitioners.
Corvalen(R) is a medical food containing pure, proprietary D-ribose, a unique sugar made by the body to synthesize many important compounds, including DNA, RNA, and, most importantly, ATP, the "energy currency" of the cells. ATP (adenosine triphosphate) is critical to health and maintaining normal energy-dependent body functions. Ribose is the essential component in the making of ATP and as a medical food, Corvalen(R) is prescribed and used under the direction of a licensed healthcare practitioner.
Clinical research has shown that Corvalen(R) can help effectively manage diseases in which there is a deficiency in energy (i.e., ATP). D-Ribose has already been shown to increase functional capacity for patients with congestive heart failure (CHF), decrease fatigue caused by Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS), and enhance energy for athletes and others who need a natural boost.
"We are terrifically enthused about advancing the entire science of wellness with Bioenergy Life Science as our alliance partner," said Randy Rose, president and CEO of Enzymatic Therapy, Inc. "The research and product development synergies we have together will bring a number of patient and consumer health solutions forward that dramatically improve the quality of life for many."
Tom VonderBrink, president and chief operating officer of Bioenergy
Life Science, concurred. "We are thrilled about the agreement with this
|SOURCE Bioenergy Life Science|
Copyright©2007 PR Newswire.
All rights reserved